Zoetis Inc. (NYSE: ZTS) Stock Competitors & Peer Comparison
See ZTS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZTS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZTS | $70.68 | -0.52% | 29.9B | 10.85 | $6.58 | +2.93% |
| TAK | $18.42 | -2.33% | 60.2B | 13.59 | $1.39 | +3.34% |
| TEVA | $38.99 | -0.51% | 45.3B | 13.27 | $2.93 | N/A |
| HLN | $9.00 | -2.86% | 40.4B | 18.78 | $0.49 | +2.16% |
| VTRS | $18.22 | +2.16% | 21.3B | 7.25 | $2.52 | +2.62% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.32 | +0.02% | 11.2B | 21.17 | $1.06 | N/A |
| RDY | $12.96 | +5.76% | 10.4B | 20.52 | $0.61 | +0.66% |
| ALKS | $40.77 | -0.20% | 6.7B | 42.26 | $0.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ZTS vs TAK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TAK has a market cap of 60.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TAK trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TAK's P/E ratio is 13.59. In terms of profitability, ZTS's ROE is +0.69%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ZTS vs TEVA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TEVA has a market cap of 45.3B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TEVA trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TEVA's P/E ratio is 13.27. In terms of profitability, ZTS's ROE is +0.69%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ZTS is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ZTS vs HLN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, HLN has a market cap of 40.4B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while HLN trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas HLN's P/E ratio is 18.78. In terms of profitability, ZTS's ROE is +0.69%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ZTS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HLN's competition here
Viatris Inc. (NASDAQ: VTRS)
ZTS vs VTRS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, VTRS has a market cap of 21.3B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while VTRS trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas VTRS's P/E ratio is 7.25. In terms of profitability, ZTS's ROE is +0.69%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ZTS is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ZTS vs ITCI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZTS's ROE is +0.69%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ZTS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ZTS vs CTLT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZTS's ROE is +0.69%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ZTS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ZTS vs ELAN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ELAN has a market cap of 11.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ELAN trades at $22.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ELAN's P/E ratio is 21.17. In terms of profitability, ZTS's ROE is +0.69%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ZTS is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ZTS vs RDY Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while RDY trades at $12.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas RDY's P/E ratio is 20.52. In terms of profitability, ZTS's ROE is +0.69%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ZTS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ZTS vs ALKS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ALKS has a market cap of 6.7B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ALKS trades at $40.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ALKS's P/E ratio is 42.26. In terms of profitability, ZTS's ROE is +0.69%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ZTS is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ZTS vs AMRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AMRX has a market cap of 6.5B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AMRX trades at $20.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AMRX's P/E ratio is 22.78. In terms of profitability, ZTS's ROE is +0.69%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ZTS is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ZTS vs LNTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while LNTH trades at $99.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas LNTH's P/E ratio is 16.76. In terms of profitability, ZTS's ROE is +0.69%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZTS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ZTS vs INDV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while INDV trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas INDV's P/E ratio is 10.10. In terms of profitability, ZTS's ROE is +0.69%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ZTS is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
ZTS vs ALVOW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ALVOW has a market cap of 3.5B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ALVOW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ALVOW's P/E ratio is 55.38. In terms of profitability, ZTS's ROE is +0.69%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ZTS is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ZTS vs RGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, RGC has a market cap of 3.1B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while RGC trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas RGC's P/E ratio is -436.62. In terms of profitability, ZTS's ROE is +0.69%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ZTS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ZTS vs SUPN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SUPN trades at $43.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SUPN's P/E ratio is 14.58. In terms of profitability, ZTS's ROE is +0.69%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ZTS is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SUPN's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ZTS vs HCM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while HCM trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas HCM's P/E ratio is 5.30. In terms of profitability, ZTS's ROE is +0.69%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ZTS is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ZTS vs DCPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZTS's ROE is +0.69%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ZTS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DCPH's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ZTS vs BHC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while BHC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas BHC's P/E ratio is 1.47. In terms of profitability, ZTS's ROE is +0.69%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ZTS is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check BHC's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ZTS vs AVDL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ZTS's ROE is +0.69%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ZTS vs TRLV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TRLV has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TRLV trades at $12.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TRLV's P/E ratio is -5.02. In terms of profitability, ZTS's ROE is +0.69%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ZTS is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
ZTS vs PRGO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PRGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PRGO's P/E ratio is 6.03. In terms of profitability, ZTS's ROE is +0.69%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ZTS is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PRGO's competition here
Alvotech (NASDAQ: ALVO)
ZTS vs ALVO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ALVO has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ALVO trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ALVO's P/E ratio is -10.42. In terms of profitability, ZTS's ROE is +0.69%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ZTS is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ALVO's competition here
Embecta Corp. (NASDAQ: EMBCV)
ZTS vs EMBCV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.69%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ZTS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ZTS vs DVAX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ZTS's ROE is +0.69%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZTS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ZTS vs ANIP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ANIP trades at $73.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ANIP's P/E ratio is 9.10. In terms of profitability, ZTS's ROE is +0.69%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ZTS is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ZTS vs ETON Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ETON trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ETON's P/E ratio is 155.74. In terms of profitability, ZTS's ROE is +0.69%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ZTS is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ZTS vs TARO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZTS's ROE is +0.69%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ZTS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ZTS vs PAHC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PAHC trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PAHC's P/E ratio is 12.18. In terms of profitability, ZTS's ROE is +0.69%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ZTS is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ZTS vs CRON Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CRON trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CRON's P/E ratio is 17.46. In terms of profitability, ZTS's ROE is +0.69%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ZTS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ZTS vs AMPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AMPH trades at $27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AMPH's P/E ratio is 9.35. In terms of profitability, ZTS's ROE is +0.69%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ZTS is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ZTS vs HROW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while HROW trades at $31.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas HROW's P/E ratio is -31.92. In terms of profitability, ZTS's ROE is +0.69%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ZTS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HROW's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ZTS vs PCRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PCRX has a market cap of 998.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PCRX trades at $25.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PCRX's P/E ratio is 9.77. In terms of profitability, ZTS's ROE is +0.69%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ZTS vs PETQ Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZTS's ROE is +0.69%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ZTS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ZTS vs COLL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, COLL has a market cap of 734M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while COLL trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas COLL's P/E ratio is 2.84. In terms of profitability, ZTS's ROE is +0.69%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ZTS is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ZTS vs IRWD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, IRWD has a market cap of 678.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas IRWD's P/E ratio is 5.28. In terms of profitability, ZTS's ROE is +0.69%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ZTS is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check IRWD's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ZTS vs AQST Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AQST has a market cap of 596M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AQST trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AQST's P/E ratio is -7.31. In terms of profitability, ZTS's ROE is +0.69%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ZTS is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AQST's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ZTS vs BDSI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZTS's ROE is +0.69%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZTS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
ZTS vs EVO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, EVO has a market cap of 564.8M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while EVO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas EVO's P/E ratio is -2.25. In terms of profitability, ZTS's ROE is +0.69%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ZTS is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check EVO's competition here
Glass House Brands Inc (NYSE: GLAS)
ZTS vs GLAS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, GLAS has a market cap of 529.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while GLAS trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas GLAS's P/E ratio is -12.22. In terms of profitability, ZTS's ROE is +0.69%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ZTS is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
ZTS vs EOLS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, EOLS has a market cap of 524.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while EOLS trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas EOLS's P/E ratio is -25.21. In terms of profitability, ZTS's ROE is +0.69%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ZTS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ZTS vs KMDA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, KMDA has a market cap of 497.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while KMDA trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas KMDA's P/E ratio is 22.68. In terms of profitability, ZTS's ROE is +0.69%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ZTS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ZTS vs TKNO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TKNO has a market cap of 493.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TKNO trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TKNO's P/E ratio is -29.68. In terms of profitability, ZTS's ROE is +0.69%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ZTS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ZTS vs TLRY Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TLRY has a market cap of 449.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TLRY trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TLRY's P/E ratio is -3.71. In terms of profitability, ZTS's ROE is +0.69%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ZTS is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ZTS vs CGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CGC has a market cap of 390.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CGC trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CGC's P/E ratio is -2.07. In terms of profitability, ZTS's ROE is +0.69%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ZTS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CGC's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ZTS vs EBS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, EBS has a market cap of 354M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while EBS trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas EBS's P/E ratio is 4.76. In terms of profitability, ZTS's ROE is +0.69%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ZTS vs ALIM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZTS's ROE is +0.69%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ZTS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ZTS vs LNDC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZTS's ROE is +0.69%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ZTS is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ZTS vs ACB Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ACB has a market cap of 253.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ACB trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ACB's P/E ratio is -2.95. In terms of profitability, ZTS's ROE is +0.69%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ZTS is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ZTS vs SIGA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SIGA has a market cap of 248.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SIGA trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SIGA's P/E ratio is 12.81. In terms of profitability, ZTS's ROE is +0.69%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ZTS is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ZTS vs LFCR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, LFCR has a market cap of 244.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while LFCR trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas LFCR's P/E ratio is -5.13. In terms of profitability, ZTS's ROE is +0.69%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ZTS is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
ZTS vs TYHT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZTS's ROE is +0.69%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ZTS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TYHT's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ZTS vs CRDL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CRDL has a market cap of 194.8M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CRDL trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CRDL's P/E ratio is -6.73. In terms of profitability, ZTS's ROE is +0.69%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ZTS is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ZTS vs ORGO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ORGO has a market cap of 177.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ORGO trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ORGO's P/E ratio is 46.00. In terms of profitability, ZTS's ROE is +0.69%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ZTS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ZTS vs REPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZTS's ROE is +0.69%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZTS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ZTS vs DERM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while DERM trades at $6.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas DERM's P/E ratio is -29.23. In terms of profitability, ZTS's ROE is +0.69%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ZTS is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DERM's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ZTS vs THTX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas THTX's P/E ratio is -28.83. In terms of profitability, ZTS's ROE is +0.69%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ZTS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check THTX's competition here
Organigram Global Inc. (NASDAQ: OGI)
ZTS vs OGI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, OGI has a market cap of 152.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while OGI trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas OGI's P/E ratio is 2.44. In terms of profitability, ZTS's ROE is +0.69%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ZTS is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check OGI's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ZTS vs ASRT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ZTS's ROE is +0.69%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ZTS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ZTS vs SCTL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZTS's ROE is +0.69%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZTS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SCTL's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ZTS vs CPIX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CPIX has a market cap of 115.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CPIX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CPIX's P/E ratio is -19.30. In terms of profitability, ZTS's ROE is +0.69%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ZTS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
ZTS vs PROC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZTS's ROE is +0.69%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZTS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ZTS vs OPTN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZTS's ROE is +0.69%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ZTS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ZTS vs ZOM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZTS's ROE is +0.69%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ZTS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ZTS vs GRVI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZTS's ROE is +0.69%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ZTS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check GRVI's competition here
BGM Group Ltd. (NASDAQ: BGM)
ZTS vs BGM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, BGM has a market cap of 88.8M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while BGM trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas BGM's P/E ratio is -1.46. In terms of profitability, ZTS's ROE is +0.69%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ZTS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check BGM's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ZTS vs ZYNE Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZTS's ROE is +0.69%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZTS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ZTS vs SSIC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZTS's ROE is +0.69%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ZTS is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
ZTS vs TLPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TLPH has a market cap of 61.8M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TLPH's P/E ratio is -3.84. In terms of profitability, ZTS's ROE is +0.69%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ZTS is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TLPH's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ZTS vs ZYBT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ZYBT has a market cap of 61.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ZYBT trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ZYBT's P/E ratio is -6.32. In terms of profitability, ZTS's ROE is +0.69%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ZTS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZYBT's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ZTS vs VLNS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZTS's ROE is +0.69%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZTS is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check VLNS's competition here
InterCure Ltd. (NASDAQ: INCR)
ZTS vs INCR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, INCR has a market cap of 60.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while INCR trades at $5.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas INCR's P/E ratio is -4.92. In terms of profitability, ZTS's ROE is +0.69%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ZTS is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check INCR's competition here
DURECT Corporation (NASDAQ: DRRX)
ZTS vs DRRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ZTS's ROE is +0.69%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ZTS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ZTS vs JUPW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZTS's ROE is +0.69%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ZTS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ZTS vs QLI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZTS's ROE is +0.69%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZTS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check QLI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ZTS vs RMTI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, RMTI has a market cap of 34.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while RMTI trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas RMTI's P/E ratio is -6.44. In terms of profitability, ZTS's ROE is +0.69%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ZTS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ZTS vs HEXO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZTS's ROE is +0.69%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZTS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check HEXO's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ZTS vs CPHI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CPHI trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CPHI's P/E ratio is -1.69. In terms of profitability, ZTS's ROE is +0.69%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ZTS is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ZTS vs TXMD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, TXMD has a market cap of 24.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while TXMD trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas TXMD's P/E ratio is 106.47. In terms of profitability, ZTS's ROE is +0.69%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ZTS vs CYTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZTS's ROE is +0.69%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ZTS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ZTS vs AYTU Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AYTU has a market cap of 23.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AYTU trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AYTU's P/E ratio is -0.47. In terms of profitability, ZTS's ROE is +0.69%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ZTS is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ZTS vs EVOK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ZTS's ROE is +0.69%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ZTS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ZTS vs OPTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, OPTH has a market cap of 15.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while OPTH trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas OPTH's P/E ratio is -3.37. In terms of profitability, ZTS's ROE is +0.69%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ZTS is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ZTS vs ACRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZTS's ROE is +0.69%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ZTS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ZTS vs CABR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, CABR has a market cap of 11.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while CABR trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas CABR's P/E ratio is -1.59. In terms of profitability, ZTS's ROE is +0.69%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ZTS is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ZTS vs AGRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZTS's ROE is +0.69%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ZTS is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ZTS vs NLTX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZTS's ROE is +0.69%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ZTS is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ZTS vs LCI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZTS's ROE is +0.69%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZTS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ZTS vs ADMP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZTS's ROE is +0.69%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZTS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ADMP's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ZTS vs GELS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while GELS trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas GELS's P/E ratio is -1.09. In terms of profitability, ZTS's ROE is +0.69%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ZTS is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
ZTS vs YCBD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, YCBD has a market cap of 4.9M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while YCBD trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas YCBD's P/E ratio is -1.14. In terms of profitability, ZTS's ROE is +0.69%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ZTS is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
ZTS vs MNK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas MNK's P/E ratio is -0.44. In terms of profitability, ZTS's ROE is +0.69%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ZTS vs FLGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ZTS's ROE is +0.69%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ZTS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ZTS vs UPC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while UPC trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas UPC's P/E ratio is -0.61. In terms of profitability, ZTS's ROE is +0.69%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ZTS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check UPC's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ZTS vs PLXP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ZTS's ROE is +0.69%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ZTS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check PLXP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ZTS vs INM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, INM has a market cap of 2.5M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while INM trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas INM's P/E ratio is -0.25. In terms of profitability, ZTS's ROE is +0.69%, compared to INM's ROE of -1.35%. Regarding short-term risk, ZTS is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check INM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ZTS vs SHPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SHPH trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SHPH's P/E ratio is -0.19. In terms of profitability, ZTS's ROE is +0.69%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ZTS is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ZTS vs ATNX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ZTS's ROE is +0.69%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ZTS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ZTS vs SNOA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, SNOA has a market cap of 2.1M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas SNOA's P/E ratio is -1.14. In terms of profitability, ZTS's ROE is +0.69%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ZTS is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ZTS vs PROCW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 29.9B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ZTS is priced at $70.68 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 10.85, whereas PROCW's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.69%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ZTS is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PROCW's competition here